Welcome to our dedicated page for Quanterix news (Ticker: QTRX), a resource for investors and traders seeking the latest updates and insights on Quanterix stock.
Quanterix Corporation develops and commercializes ultra-sensitive biomarker tools for life sciences research and clinical testing. Its business includes Simoa instruments, assay kits, consumables, spatial biology systems, contract research services, and clinical laboratory testing through its Accelerator Laboratory and Lucent Diagnostics brand.
QTRX news commonly covers biomarker testing for cognitive disease, including blood-based Alzheimer’s disease panels, collaborations that connect Lucent Diagnostics tests with clinical and community workflows, and updates tied to operating results. Company developments also include shareholder voting matters, governance changes, capital-structure disclosures, and clinical or regulatory topics related to its diagnostic and research offerings.
Quanterix (Nasdaq: QTRX) has appointed experienced healthcare executive Jim Gute as Chief Commercial Officer, based at its Billerica, MA headquarters. He is charged with leading a re-acceleration of growth in commercial operations as the company prepares to expand its diagnostics business and strengthen its core offerings.
According to Quanterix, Gute brings about 20 years of senior commercial leadership, including roles as President of GE Healthcare and Senior Vice President and Commercial Manager, General Screening, at Exact Sciences, a company with nearly $3 billion in revenue prior to its acquisition by Abbott Labs in early 2026.
Quanterix (NASDAQ: QTRX) reported second quarter 2026 revenue of $32.9 million, up 34% year over year, with GAAP gross margin of 38.5% and non-GAAP gross margin of 47.9%. Adjusted EBITDA loss was $10.0 million, an improvement from a $13.7 million loss a year ago. The company ended the quarter with $96.9 million in cash, cash equivalents, marketable securities, and restricted cash, and adjusted cash usage was $4.0 million.
Quanterix completed its ERP integration from the Akoya acquisition, achieving $85 million in annualized savings, but recorded a $26.9 million goodwill impairment related to Akoya. Leadership additions included a new Chief Commercial Officer, COO, CFO, and Diagnostics GM. In Alzheimer’s, Anthem Blue Cross and Blue Shield began covering qualifying blood-based biomarker tests, including Lucent AD® Complete, and new clinical data supported the company’s multi-analyte approach. Quanterix was also selected as a co-investigator in the PD-BUILD Parkinson’s biomarker program and launched new Simoa and spatial products.
For 2026, Quanterix now expects revenue of $142–$148 million (down from $169–$174 million), non-GAAP gross margin of 48–50% (previously 49–53%), cash flow breakeven in 2027, and a year-end 2026 cash balance of about $80 million, with no debt.
Quanterix (Nasdaq: QTRX) announced that senior management will participate in the Canaccord Genuity Capital Markets 46th Annual Growth Conference at the Intercontinental Hotel in Boston on August 11-12, 2026. CEO Everett Cunningham will join a webcast fireside chat at 1:00 pm ET on August 12, providing a company and strategic update.
Chief Technology and Product Officer Michael Miller will join a Neurology Diagnostics panel at 2:00 pm ET the same day. Quanterix is also arranging one-on-one investor meetings involving Cunningham, CFO Jason Faessler and Miller. The live webcast and replay will be available via the company’s Investor Relations website.
Quanterix (Nasdaq: QTRX) will hold a conference call on Monday, August 10, 2026, at 8:30 AM ET to discuss its second quarter 2026 financial results. According to Quanterix, a press release with these results will be issued earlier that day and posted on its website.
Investors may join the call via USA & Canada toll-free dial-in (800) 715-9871 or (646) 307-1963 using conference ID 9896910, or listen through a live webcast in the Investors section of the Quanterix website. An archived webcast replay will be available for one year.
Quanterix (NASDAQ: QTRX) reported that on July 15, 2026, it made an inducement equity grant to Jason Faessler in connection with his commencement as Chief Financial Officer and Treasurer. The award consists of 141,820 restricted stock units (RSUs), each representing one share of Quanterix common stock.
According to Quanterix, the RSUs vest in four equal annual installments on the first four anniversaries of the grant date, subject to Mr. Faessler’s continued employment with the company or its subsidiaries. The grant was made under the Amended and Restated 2025 Inducement Plan as an inducement material to entering employment, in line with Nasdaq Listing Rule 5635(c)(4), and was approved by the Board’s Compensation Committee.
Quanterix (NASDAQ: QTRX) announced multiple milestones supporting broader clinical adoption of its LucentAD® Complete blood-based Alzheimer’s test. Beginning July 1, 2026, Anthem Blue Cross and Blue Shield medical policies cover qualifying blood-based biomarker testing, including LucentAD Complete, for eligible members meeting medical-necessity criteria, potentially impacting about 40 million members across 14 states.
According to Quanterix, a new peer‑reviewed study showed LucentAD Complete achieved high diagnostic parity versus an IP‑MS method and reduced diagnostic ambiguity about three-fold versus standalone plasma p‑Tau217. New AAIC 2026 data also support multi-analyte testing for earlier detection, with a 520-participant community study identifying preclinical Alzheimer’s in about 20% of cognitively normal adults.
Quanterix (NASDAQ: QTRX) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) to three new employees effective June 15, 2026. The awards comprise 336,804 restricted stock units that vest in four equal annual installments, contingent on continued employment, under the Amended and Restated 2025 Inducement Plan.
Quanterix (Nasdaq: QTRX) appointed Jason Faessler as Chief Financial Officer, effective June 22. Faessler has extensive finance leadership experience in the life science tools industry, including senior roles at Bruker, PAREXEL, EMC (now Dell), and Harvard Business Publishing, supporting Quanterix’s strategic growth plans.
Quanterix (Nasdaq: QTRX) appointed Geoff Albrecht as Senior Vice President and General Manager of Diagnostics, effective June 4, 2026.
He will lead Diagnostics strategy, initially focused on Alzheimer’s disease diagnostics, reporting to the CEO and joining the Executive Leadership Team.
Albrecht previously managed about $2.9 billion in revenue as Regional Vice President at Quest Diagnostics and brings extensive experience in commercial leadership, partnerships, operations, and governance.
Quanterix (Nasdaq: QTRX) announced that senior management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL, from June 8-10, 2026.
CEO Everett Cunningham will join a fireside chat on June 9 at 1:20 pm ET, with a live webcast and replay available on the company’s investor relations website.